Long-term vasodilator therapy of chronic aortic insufficiency. A randomized double-blinded, placebo-controlled clinical trial.
Although vasodilator drugs acutely reduce regurgitation and improve cardiac performance in aortic insufficiency, their long-term effects on left ventricular size and function are uncertain. Consequently, we performed a double-blinded, placebo-controlled trial using hydralazine in 80 minimally symptomatic patients who had clinically stable, moderate-to-severe aortic insufficiency. Patients randomized to hydralazine displayed a progressive reduction in left ventricular end-diastolic volume index (LVEDVI) measured by radionuclide angiography, the predetermined end point of the study. At 24 months, mean LVEDVI had been reduced by 30 +/- 38 ml/m2, an 18% reduction from baseline. In contrast, LVEDVI changed minimally in patients randomized to placebo, and the intergroup differences over time were statistically significant (p less than 0.03). The hydralazine group also experienced reductions in left ventricular end-systolic volume index and increases in ejection fraction that were significantly different (both p less than 0.01) from changes in placebo-treated patients. These findings show that long-term treatment with hydralazine reduces the volume overload in aortic insufficiency and suggest that such therapy may have a beneficial effect on the natural history of the disease.
Greenberg
B
B
Department of Medicine, Oregon Health Sciences University, Portland 97201.
Massie
B
B
Bristow
J D
JD
Cheitlin
M
M
Siemienczuk
D
D
Topic
N
N
Wilson
R A
RA
Szlachcic
J
J
Thomas
D
D
D000284:Administration, Oral; D000328:Adult; D001022:Aortic Valve Insufficiency / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D001810:Blood Volume; D002986:Clinical Trials as Topic; D003971:Diastole; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006352:Heart Ventricles / Q000503:physiopathology; D006801:Humans; D006830:Hydralazine / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011875:Radionuclide Angiography; D011897:Random Allocation
D006830:Hydralazine